Literature DB >> 12460933

Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.

Lodewyk F A Wessels1, Tibor van Welsem, Augustinus A M Hart, Laura J van't Veer, Marcel J T Reinders, Petra M Nederlof.   

Abstract

In approximately 70% of the families with a high frequency of early-onset breast and/or ovarian cancer, BRCA1 or BRCA2 germline mutations cannot be identified with the current screening regime. Therefore, we used data mining to identify a somatic genetic signature to differentiate BRCA1 mutation carriers from non-BRCA1 carriers based on the genetic characteristics of their breast carcinomas. For this purpose, we developed a molecular classifier, which assigns a given tumor to either the BRCA1 or control group based on somatic genetic profiles as revealed by comparative genomic hybridization. This was performed on breast tumors selected from two groups of patients: 28 proven BRCA1 germline mutation carriers; and a control group consisting of 42 breast tumors from patients with unknown BRCA1 or BRCA2 status. We show that BRCA1 breast carcinomas exhibit specific somatic genetic aberrations and can be distinguished from control tumors with an accuracy of 84% (sensitivity of 96% and specificity of 76%). Chromosomal bands used by this classifier include regions on chromosomes 3p, 3q, and 5q. The classifier miss-assigned one patient with a BRCA1 mutation to the non-BRCA1 class. The germline mutation in this patient is a 62bp deletion in the last exon of BRCA1 (5622del62). Possibly, this mutation may give a different phenotypic effect than do mutations in other regions of the gene. Validation on an independent set of BRCA1 and sporadic tumors showed that the BRCA1 classifier correctly identified all 6 BRCA1 tumors and assigned 4 of the 19 control patients to the BRCA1 class. The resulting accuracy on the validation set is 84%.

Entities:  

Mesh:

Year:  2002        PMID: 12460933

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

Review 1.  Molecular basis for therapy resistance.

Authors:  Per E Lønning
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

2.  Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.

Authors:  Marc Tischkowitz; Nancy Hamel; Marcelo A Carvalho; Gabriel Birrane; Aditi Soni; Erik H van Beers; Simon A Joosse; Nora Wong; David Novak; Louise A Quenneville; Scott A Grist; Petra M Nederlof; David E Goldgar; Sean V Tavtigian; Alvaro N Monteiro; John A A Ladias; William D Foulkes
Journal:  Eur J Hum Genet       Date:  2008-02-20       Impact factor: 4.246

Review 3.  The changing role of pathology in breast cancer diagnosis and treatment.

Authors:  Anthony S-Y Leong; Zhengping Zhuang
Journal:  Pathobiology       Date:  2011-06-14       Impact factor: 4.342

4.  Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation.

Authors:  Frank Weber; Lei Shen; Koichi Fukino; Attila Patocs; George L Mutter; Trinidad Caldes; Charis Eng
Journal:  Am J Hum Genet       Date:  2006-04-12       Impact factor: 11.025

5.  Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer.

Authors:  Sean P Pitroda; Riyue Bao; Jorge Andrade; Ralph R Weichselbaum; Philip P Connell
Journal:  Clin Cancer Res       Date:  2017-03-24       Impact factor: 12.531

6.  A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.

Authors:  Bastiaan Evers; Eva Schut; Eline van der Burg; Tanya M Braumuller; David A Egan; Henne Holstege; Pauline Edser; David J Adams; Richard Wade-Martins; Peter Bouwman; Jos Jonkers
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

7.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.

Authors:  Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

8.  Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci.

Authors:  Marianne Berg; Trude H Agesen; Espen Thiis-Evensen; Marianne A Merok; Manuel R Teixeira; Morten H Vatn; Arild Nesbakken; Rolf I Skotheim; Ragnhild A Lothe
Journal:  Mol Cancer       Date:  2010-05-06       Impact factor: 27.401

9.  Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis.

Authors:  Meera Nanjundan; Kwai Wa Cheng; Fan Zhang; John Lahad; Wen-Lin Kuo; Rosemarie Schmandt; Karen Smith-McCune; David Fishman; Joe W Gray; Gordon B Mills
Journal:  Mol Oncol       Date:  2008-05-10       Impact factor: 6.603

10.  The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.

Authors:  William Tapper; Victoria Hammond; Sue Gerty; Sarah Ennis; Peter Simmonds; Andrew Collins; Diana Eccles
Journal:  Breast Cancer Res       Date:  2008-12-18       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.